| Literature DB >> 33172059 |
Rony Zachariah1, Stefanie Rust2, Pruthu Thekkur3,4, Mohammed Khogali1, Ajay Mv Kumar3,4,5, Karapet Davtyan6, Ermias Diro7, Srinath Satyanarayana3, Olga Denisiuk8, Johan van Griensven9, Veerle Hermans10, Selma Dar Berger3, Saw Saw11, Anthony Reid10, Abraham Aseffa1, Anthony D Harries3,12, John C Reeder1.
Abstract
Introduction: Observational studies are often inadequately reported, making it difficult to assess their validity and generalizability and judge whether they can be included in systematic reviews. We assessed the publication characteristics and quality of reporting of observational studies generated by the Structured Operational Research and Training Initiative (SORT IT).Entities:
Keywords: SORT IT; STROBE; health systems research; observational studies; operational research; universal health coverage
Year: 2020 PMID: 33172059 PMCID: PMC7709644 DOI: 10.3390/tropicalmed5040167
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Figure 1Global distribution of 392 publications from 47 completed Structured Operational Research and Training Initiative courses (January 2009–December 2018).
Characteristics of published papers from 47 completed Structured Operational Research and Training Initiative courses (January 2009–December 2018).
| Characteristics of Published Papers |
| (%) |
|---|---|---|
|
| 392 | |
|
| 50 | |
| 0–19 | ||
|
| ||
| First author | 370 | (94) |
| Corresponding author | 367 | (94) |
| Last author | 214 | (55) |
|
| ||
| Female first author | 173 | (44) |
|
| ||
| Disease control programs/Ministries of Health | 180 | (46) |
| International or national NGOs | 133 | (33) |
| Academic institutions | 63 | (16) |
| WHO | 12 | (3) |
| Donors | 4 | (1) |
|
| ||
| Mean number from HICs (range) | 2.2 | (0–8) |
| Mean number from LMICs (range) | 3.6 | (0–9) |
| HIC-LMIC partnerships ( | 27 | (87) 1 |
| LMIC-LMIC partnerships ( | 325 | (90) 2 |
|
| ||
| Included in background and/or analysis | 204 | (52) |
|
| ||
| Immediate open access | 349 | (89) |
| Delayed open access | 13 | (3) |
| Subscription-based | 30 | (8) |
|
| ||
| Papers with article view metrics | 153 | (39) |
| Total views | 271428 | |
|
| ||
| Papers with article download metrics | 95 | (24) |
| Total downloads | 9127 | |
|
| ||
| Papers with article citation metrics | 153 | (39) |
| Total citations | 998 |
1 High income country (HIC)—low- and middle-income country (LMIC) partnership was when the principal investigator was from an institution in an HIC (n−31) but authors from an LMIC were included as co-authors. 2 An LMIC-LMIC partnership was when the principal investigator was from an LMIC (n−361) and there was also a co-author(s) from at least one different institution from another LMIC country other than that of the principal investigator.
Completeness of reporting of publications from 47 completed Structured Operational Research and Training Initiative courses according to an adapted STROBE checklist (January 2009–December 2018).
| Completeness of Reporting |
| (%) |
|---|---|---|
|
| 392 | |
|
| ||
| >85% (Excellent) | 346 | (88.3) |
| 76–85% (Good) | 41 | (10.4) |
| 65–75% (Fair) | 5 | (1.3) |
| <65% (Unsatisfactory) | 0 | (0) |
STROBE: Structured Reporting of Observational Studies in Epidemiology. a Assessed on 24 items in an adapted STROBE checklist.
Percentage of items in the STROBE checklist which were reported in 392 studies (179 cohort, six case control and 207 cross-sectional studies) from the Structured Operational Research and Training Initiative (2009–2018).
| Item | Recommendation | Reported n (%) | Not Reported n (%) | Not Applicable n (%) |
|---|---|---|---|---|
| 1a | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 264 (67.3) | 128 (32.7) | 0 |
| 1b | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 390 (99.5) | 2 (0.5) | 0 |
| 2 | Explain the scientific background and rationale for the investigation being reported | 392 (100) | 0 | 0 |
| 3 | State specific objectives, including any pre-specified hypotheses | 391 (99.7) | 1 (0.3) | 0 |
| 4 | Present key elements of study design early in the paper | 392 (100) | 0 | 0 |
| 5a–g | Describe: setting, locations, relevant dates, periods of recruitment, exposure, follow-up, data | 392 (100) | 0 | 0 |
| 6a | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. If applicable, describe methods of follow-up | 179 (100) | 0 | 0 |
| 6b | Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | 6 (100) | 0 | 0 |
| 6c | Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants if applicable | 206 (99.5) | 1 (0.5) | 0 |
| 6d | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed | 0 | 0 | 179 (100) 1 |
| 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 388 (99.0) | 4 (1.0) | 0 |
| 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 390 (99.5) | 2 (0.5) | 0 |
| 9 | Describe any efforts to address potential sources of bias | 345 (88.0) | 47 (12.0) | 0 |
| 10 | Explain how the study size was determined | 391 (99.7) | 1 (0.3) | 0 |
| 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 387 (98.7) | 0 | 5 (1.3) |
| 12a | (a) Describe all statistical methods, and if applicable, those used to control for confounding | 304 (77.6) | 4 (1.0) | 84 (21.4) |
| 12b | (b) If applicable, describe any methods used to examine subgroups and interactions | 204 (52.0) | 13 (3.3) | 175 (44.7) |
| 12c | (c) If applicable, explain how missing data were addressed. | 136 (34.7) | 69 (17.6) | 187 (47.7) |
| 12d | (d) Cohort study—If applicable, explain how loss to follow-up was addressed | 51 (28.5) | 59 (33.0) | 69 (38.5) |
| 12e | Case-control study—If applicable, explain how matching of cases and controls was addressed | 4 (66.7) | 2 (33.3) | 0 |
| 12f | Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy | 29 (14.0) | 6 (2.9) | 172 (83.1) |
| 12g | (e) If applicable, describe any sensitivity analyses | 10 (2.6) | 1 (0.3) | 381 (97.1) |
| 13a | (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed | 354 (90.3) | 0 | 38 (9.7) |
| 13b | (b) If applicable, give reasons for non-participation at each stage | 42 (10.7) | 6 (1.5) | 344 (87.8) |
| 13c | (c) If applicable, consider use of a flow diagram | 105 (26.8) | 8 (2.0) | 279 (71.2) |
| 14a | (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders | 346 (88.3) | 1 (0.3) | 45 (11.4) |
| 14b | (b) If applicable, Indicate number of participants with missing data for each variable of interest | 225 (57.4) | 25 (6.5) | 142 (36.1) |
| 14c | (c) Cohort study—If applicable, summarize follow-up time (e.g., average and total amount) | 92 (51.4) | 20 (11.2) | 67 (37.4) |
| 15a | Cohort study—Report numbers of outcome events or summary measures over time | 179 (100) 1 | 0 | 0 |
| 15b | Case-control study—Report numbers in each exposure category, or summary measures of exposure | 6 (100) 1 | 0 | 0 |
| 15c | Cross-sectional study—Report numbers of outcome events or summary measures | 196 (95) 1 | 0 | 11(5) |
| 16a | (a) If applicable, give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 286 (73.0) | 2 (0.5) | 104 (26.5) |
| 16b | (b) If applicable, report category boundaries when continuous variables were categorized | 176 (45.0) | 1 (0.3) | 215 (54.7) |
| 16c | (c) If applicable and relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 25 (6.4) | 5 (1.2) | 362 (92.4) |
| 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | 75 (19.1) | 7 (1.8) | 310 (79.1) |
| 18 | Summarize key results with reference to study objectives | 392 (100) | 0 | 0 |
| 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 388 (99.0) | 4 (1.0) | 0 |
| 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 392 (100) | 0 | 0 |
| 21 | Discuss the generalizability (external validity) of the study results | 355 (90.5) | 37 (9.5) | 0 |
| 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 390 (99.5) | 2 (0.5) | 0 |
| 23 | Local relevance of the research question indicated/mentioned in the paper | 392 (100) | 0 | 0 |
| 24 | Ethics statement included | 391 (99.8) | 1 (0.3) | 0 |
| Total Percentage |
|
|
|
1 Applicable only to cohort studies (n = 179) or cross-sectional studies (n = 207) or case control studies (n = 6).